Although our methylation studies might be underpowered to detect PROX1 mQTL effects, in the publically available ALSPAC cohort, the risk variant in PROX1 was associated with increased methylation as well as increased methylation of PROX1 was seen in type 2 diabetes individuals as compared to healthy controls. Here, PROX1 is linked to type 2 diabetes mellitus.